Published in Health and Medicine Week, December 1st, 2003
The financial terms and other details of the license were not disclosed.
"We believe that Rigel's lead drug candidate, R803, has the potential to become an anchor of therapeutic approaches to treating this intractable virus," stated James M. Gower, chairman and chief executive officer.
Rigel's lead HCV small-molecule drug candidate, R803, rapidly and selectively targets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.